Stock(600222)Hot line:010-61006450


Understand the latest news of Leadingpharm

Strategic Cooperation | The Intelligent Development Joint Research Center for Improved New Drugs Built by Leadingpharm and Peking University Third Hospital has been Officially Launched

Release time:2022-11-12
Recently,Leadingpharm and Peking University Third Hospital (PUTH) jointly established the Peking University Third Hospital - Leadingpharm Intelligent Development Joint Research Center for Improved New Drugs. Starting with drug clinical trials, pediatrics, oncology radiotherapy and other subjects, the two sides will give full play to each other's advantages to promote the development and transformation of new products and technologies. In addition, Leadingpharm and PUTH will also carry out all-round and in-depth cooperation in talent training, academic exchanges and other fields.
The establishment of Intelligent Development Joint Research Center for Improved New Drugs is an important step in the development and construction strategic planning of the improved new drug R&D sector for Leadingpharm. In the future, based on the two sides’ strong advantages in scientific research, clinical resources and clinical experts, and guided by the clinical demand, they will fully consider the three driving factors including demand, policy and technology, jointly carry out diversified R&D of improved new drugs and clinical research of innovative drugs. This cooperation accelerate the transformation of achievements, and open a new mode of cooperation between clinical research bases and R&D institutions.

Meanwhile, as the Standing Member Organization of Chinese Research Hospital Association and the Vice Chairman Member Organization of the Professional Committee of Integrated Traditional Chinese and Western Medicine New Drug Creation, Leadingpharm will actively implement the purpose and significance of the association for establishing a transformational research system integrating clinical and scientific research, and contribute to promoting the construction of Chinese Research Hospital.


PUTH is a comprehensive First Class of the Third Grade Hospital. It is the Standardized Training Base of the National Health Commission for Specialists, the Professional Base of Beijing for Standardized Residents Training in Hospital, and the Skills Assessment Center of Beijing for Standardized Residents Training in Hospital. It has 20 national key clinical sections, 70 on-the-job doctoral supervisors, 1 CAS Member, and 2 CAE Members.

As a technical service platform of PUTH for clinical trials of drugs and medical devices, the Drug Clinical Trials Institute (DCTC) of PUTH has built a One-stop Early Clinical Research Platform for innovative drugs for metabolic diseases, cardiovascular diseases and tumors, and has been responsible for the early clinical development or model guided clinical development projects of more than 40 Class 1.1 Innovative Drugs.


Leadingpharm was established in 2005, reorganized with Henan Taloph Pharmaceutical Stock in 2015 (stock code: 600222). Leadingpharm is committed to promoting the development of China's pharmaceutical industry with innovative R&D and service models, together with information technology. Based on the international perspective, Leadingpharm has formed the core competitive advantage of "internationalization, integration and industrialization". Based on its mature and complete management system of pharmaceutical R&D, rich project experience and a team of more than 1000 senior experts at home and abroad, Leadingpharm has built the CXO Whole Industry Chain Service System covering preclinical research, clinical CRO, CDMO and MAH, and achieved full coverage of innovative drugs, high-end complex preparations, cell gene therapy drugs and other fields, which can provide global customers with a truly one-stop service.